The purpose of this study is to evaluate an investigational drug called treprostinil palmitil inhalation powder (TPIP) for the treatment of pulmonary arterial hypertension (PAH). The study aims to determine the effectiveness and tolerability of TPIP, as well as how it works in the human body. Participants will be randomly assigned to receive either TPIP or placebo (inactive substance). They will also be asked to complete 6-minute walk tests, right heart catheterization, electrocardiogram (ECG) and questionnaires, among other procedures.
What is the full name of this clinical trial?
A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension